Prior and concomitant therapies.
| Treatment | All Patients, N = 127 | |
|---|---|---|
| Prior Therapies n (%) | Concomitant Therapies n (%) | |
| Methotrexate | 82 (64.6) | 56 (44.1) |
| Traditional disease-modifying antirheumatic drug | ||
| 0 | 0 | 44 (34.6) |
| 1 | 28 (22.0) | 56 (44.1) |
| 2 | 43 (33.9) | 21 (16.5) |
| 3 | 22 (17.3) | 6 (4.7) |
| ≥ 4 | 34 (26.8) | 0 |
| Biologic agent | ||
| Etanercept | 23 (18.1) | — |
| Infliximab | 16 (12.6) | — |
| Alefacept | 9 (7.1) | — |
| Efalizumab | 6 (4.7) | — |
| Other systemic therapy | ||
| Corticosteroid | 17 (13.4) | 20 (15.7) |
| Retinoid | 6 (4.7) | 0 |
| Phototherapy | ||
| Ultraviolet B light | 16 (12.6) | 0 |
| Psoralen and ultraviolet A light | 2 (1.6) | 0 |
| Topical treatment | ||
| Corticosteroid | 56 (44.1) | 24 (18.9) |
| Vitamin D analog | 24 (18.9) | 8 (6.3) |
| Other | 6 (4.7) | 17 (13.4) |